about
Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study.Prediction of mortality and functional decline by changes in eGFR in the very elderly: the Leiden 85-plus studyThe glomerular filtration rate estimated by new and old equations as a predictor of important outcomes in elderly patients.Short-term prognostic value of forced expiratory volume in 1 second divided by height cubed in a prospective cohort of people 80 years and older.The correlation between blood pressure and kidney function decline in older people: a registry-based cohort study.The clinical impact of valvular heart disease in a population-based cohort of subjects aged 80 and olderA High Sense of Coherence as Protection Against Adverse Health Outcomes in Patients Aged 80 Years and Older.Long-term evolution of renal function in patients with type 2 diabetes mellitus: a registry-based retrospective cohort study.Significance of serum immune markers in identification of global functional impairment in the oldest old: cross-sectional results from the BELFRAIL study.Methods to evaluate renal function in elderly patients: a systematic literature review.Correlates of dyspnoea and its association with adverse outcomes in a cohort of adults aged 80 and over.CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study.Predictive Value of Different Expressions of Forced Expiratory Volume in 1 Second (FEV1) for Adverse Outcomes in a Cohort of Adults Aged 80 and Older.Prevalence and Prognostic Impact of Valve Area-Gradient Patterns in Patients ≥80 Years With Moderate-to-Severe Aortic Stenosis (from the Prospective BELFRAIL Study).Interleukin-6 as a first-rated serum inflammatory marker to predict mortality and hospitalization in the oldest old: A regression and CART approach in the BELFRAIL study.Multimorbidity measures were poor predictors of adverse events in patients aged ≥80 years: a prospective cohort study.General practitioners' judgement of chronic heart failure in the oldest old: Insights from the BELFRAIL study.No relation between CMV infection and mortality in the oldest old: results from the Belfrail study.CD4:8 ratio >5 is associated with a dominant naive T-cell phenotype and impaired physical functioning in CMV-seropositive very elderly people: results from the BELFRAIL study.Association between traditional cardiovascular risk factors and mortality in the oldest old: untangling the role of frailty.An alternative classification system for chronic kidney disease.The evolution of renal function and the incidence of end-stage renal disease in patients aged ≥ 50 years.No relation between vitamin D status and physical performance in the oldest old: results from the Belfrail study.Prognostic value of short-term decline of forced expiratory volume in 1 s over height cubed (FEV1/Ht(3)) in a cohort of adults aged 80 and over.Estimating the prevalence of diabetes mellitus and thyroid disorders using medication data in Flanders, Belgium.The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older.Airflow limitation by the Global Lungs Initiative equations in a cohort of very old adults.The prevalence and detection of chronic kidney disease (CKD)-related metabolic complications as a function of estimated glomerular filtration rate in the oldest old.Respiratory function and its predictive value for health related outcomes in the BELFRAIL cohort.Patient and treatment characteristics associated with patient activation in patients undergoing hemodialysis: a cross-sectional study.Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based studyMuscle Strength and Physical Performance as Predictors of Mortality, Hospitalization, and Disability in the Oldest OldIs there a correlation between an eGFR slope measured over a 5-year period and incident cardiovascular events in the following 5 years among a Flemish general practice population: a retrospective cohort studyBurden of heart failure in Flemish general practices: a registry-based study in the Intego databaseTrends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015Predictive Accuracy of Frailty Tools for Adverse Outcomes in a Cohort of Adults 80 Years and Older: A Decision Curve AnalysisSelf-management among community-dwelling people with chronic conditions: Adapting evidence-based group programs using intervention mapping
P50
Q34543951-228CD33E-6EE4-4341-A1DD-E3E96C488CBEQ34777391-977F8786-9EC9-4853-98D4-E1B0740E8130Q35091993-47B72D25-1C06-404D-ABE8-9BEA06A8D93DQ35132966-33135261-11E3-465E-8A6E-80663BEB2280Q35803257-B5160F43-AAFB-4EC0-8063-0512C6787E42Q35891148-2BE6AD41-9784-45D0-8A3E-B375BF7AEB86Q37084055-48116323-9917-4E9E-BA30-4BDD971060EDQ37449259-AA9D9EB2-37ED-433A-A1CD-D414ABBBD3F6Q37470982-37F77611-B00D-4800-98B3-F22E2DF01A7EQ37780615-45D74988-80FA-41FE-B7A9-BAFF877BB6E6Q38716931-F800E959-1589-4947-A5AE-F9216F3D045CQ39121923-309F342A-3847-4F0D-A39B-D487BB802961Q39280372-43DB7243-1208-4EF9-8644-724CD96D4A48Q40685585-21417135-1E81-435D-B28A-EEE3D96E7F5BQ40860936-9B99D8BF-F188-4186-BDB3-236C58DF3E64Q41657931-DD6F27F0-6D7A-46E2-BADD-83220AEFC0B5Q41731992-EC242075-07D4-4800-87D8-58F21E64E3B0Q42206108-CA419391-CD3C-4F84-88D5-C475ADFEF1ABQ42227108-AA6ACBCA-688B-4ECE-84DD-F36CA8A693CBQ42376632-7DC0538C-B3DC-40B3-A1DD-48C41CD59432Q43557142-04D5001A-BF59-40B8-8FBB-D9FD2FA2ED26Q44585749-BAAA85EE-FA86-4509-B3C3-4091D942EAC8Q45353188-5F8C6F69-1B15-4B7F-B9E3-80BA5E564F6BQ47203783-4DCA744B-F75C-4A9E-B2E1-E61544660F9AQ47827434-A88CC312-CCB5-4107-B951-C4203B35704CQ48373695-2469B55D-D2AA-4B9E-BBE8-6B93D6236FDCQ50930003-316BF4C8-12EE-4653-A39F-45CA1C02AD61Q51441288-580369AD-EE89-4D4C-A2D7-B357A9587D7FQ54195717-E5009A90-EF81-439F-BE44-DB565656229BQ54980721-C4A20B0A-60D1-4D37-BBBA-4810204656EBQ58605269-FCCC80FB-340B-42DD-8434-B9E8D2722765Q58899559-D0337D1D-6B71-4BCF-96BB-F881B6FA32A2Q59809814-C7FCA6A1-2FDA-4717-A985-E5861537B2E9Q61450618-AD3EED64-0563-4B7B-8718-63A31200A731Q64238401-B1726E87-BBFB-4D43-A914-E6ECB7AE1B3BQ91069267-040221D3-BD14-44F9-9CFE-62C48722637EQ91194073-395C1E69-5E16-440A-98D7-B3CC64E86A58
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gijs Van Pottelbergh
@ast
Gijs Van Pottelbergh
@en
Gijs Van Pottelbergh
@es
Gijs Van Pottelbergh
@nl
type
label
Gijs Van Pottelbergh
@ast
Gijs Van Pottelbergh
@en
Gijs Van Pottelbergh
@es
Gijs Van Pottelbergh
@nl
prefLabel
Gijs Van Pottelbergh
@ast
Gijs Van Pottelbergh
@en
Gijs Van Pottelbergh
@es
Gijs Van Pottelbergh
@nl
P106
P31
P496
0000-0002-4189-3517